These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 444336)

  • 21. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 22. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
    Rinne UK; Birket-Smith E; Dupont E; Hansen E; Hyyppä M; Marttila R; Mikkelsen B; Pakkenberg H; Presthus J
    J Neurol; 1975 Dec; 211(1):1-9. PubMed ID: 56427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 24. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 26. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A
    Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract]   [Full Text] [Related]  

  • 28. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 29. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 36. MPTP: clinical implications.
    Stern G
    J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A; Mars H; Botez MI; Joubert M
    Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
    Arai H; Shinotoh H; Hattori T
    Rinsho Shinkeigaku; 1997 Mar; 37(3):264-5. PubMed ID: 9217430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.